New drug tracking study aims to learn how saruparib moves through the body
NCT ID NCT06713369
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 31 times
Summary
This early-phase study looks at how the drug saruparib is absorbed, distributed, broken down, and removed from the body in 8 people with advanced solid tumors. Participants receive a single oral dose and a single intravenous dose with a radioactive tracer to track the drug. The goal is to gather information, not to treat the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGLiverpool, L7 8YA, United Kingdom
-
Research Site
RECRUITINGManchester, M20 4BX, United Kingdom
Conditions
Explore the condition pages connected to this study.